Sarcopenia Explained

Sarcopenia
Field:Geriatrics
Rheumatology

Sarcopenia (ICD-10 code M62.84) is a type of muscle loss that occurs with aging and/or immobility. It is characterized by the degenerative loss of skeletal muscle mass, quality, and strength. The rate of muscle loss is dependent on exercise level, co-morbidities, nutrition and other factors. The muscle loss is related to changes in muscle synthesis signalling pathways. It is distinct from cachexia, in which muscle is degraded through cytokine-mediated degradation, although the two conditions may co-exist. Sarcopenia is considered a component of frailty syndrome.[1] Sarcopenia can lead to reduced quality of life, falls, fracture, and disability.[2] [3]

Sarcopenia is a factor in changing body composition. When associated with aging populations, certain muscle regions are expected to be affected first, specifically the anterior thigh and abdominal muscles.[2] [4] In population studies, body mass index (BMI) is seen to decrease in aging populations while bioelectrical impedance analysis (BIA) shows body fat proportion rising.[5]

Etymology

The term sarcopenia stems from Greek σάρξ sarx, "flesh" and πενία penia, "poverty". This was first proposed by Rosenberg in 1989, who wrote that "there may be no single feature of age-related decline that could more dramatically affect ambulation, mobility, calorie intake, and overall nutrient intake and status, independence, breathing, etc".

Sarcopenia is distinct from cachexia, in which muscle is degraded through cytokine-mediated degradation, although the two conditions may co-exist.

Signs and symptoms

The hallmark sign of sarcopenia is loss of lean muscle mass, or muscle atrophy. The change in body composition may be difficult to detect due to obesity, changes in fat mass, or edema. Changes in weight, limb or waist circumference are not reliable indicators of muscle mass changes. Sarcopenia may also cause reduced strength, functional decline and increased risk of falling. Sarcopenia may also have no symptoms until it is severe and is often unrecognized. Research has shown, however, that hypertrophy may occur in the upper parts of the body to compensate for this loss of lean muscle mass[2] [6] Therefore, one early indicator of the onset of sarcopenia can be significant loss of muscle mass in the anterior thigh and abdominal muscles.[2]

Causes

There are many proposed causes of sarcopenia and it is likely the result of multiple interacting factors. Understanding of the causes of sarcopenia is incomplete, however changes in hormones, immobility, age-related muscle changes, nutrition and neurodegenerative changes have all been recognized as potential causative factors.

The degree of sarcopenia is determined by two factors: the initial amount of muscle mass and the rate at which muscle mass declines. Due to variations in these factors across the population, the rate of progression and the threshold at which muscle loss becomes apparent is variable.[7] Immobility dramatically increases the rate of muscle loss, even in younger people. Other factors that can increase the rate of progression of sarcopenia include decreased nutrient intake, low physical activity, or chronic disease. Additionally, epidemiological research has indicated that early environmental influences may have long-term effects on muscle health. For example, low birth weight, a marker of a poor early environment, is associated with reduced muscle mass and strength in adult life.[8] [9] [10]

Pathophysiology

There are multiple theories proposed to explain the mechanisms of muscle changes of sarcopenia including changes in myosatellite cell recruitment, changes in anabolic signalling, protein oxidation, inflammation, and developmental factors. The pathologic changes of sarcopenia include a reduction in muscle tissue quality as reflected in the replacement of muscle fibers with fat, an increase in fibrosis, changes in muscle metabolism, oxidative stress, and degeneration of the neuromuscular junction.[11] The failure to activate satellite cells upon injury or exercise is also thought to contribute to the pathophysiology of sarcopenia. Additionally, oxidized proteins can lead to a buildup of lipofuscin and cross-linked proteins causing an accumulation of non-contractile material in the skeletal muscle and contribute to sarcopenic muscle.

In sarcopenic muscle the distribution of the types of muscle fibers changes with a decrease in type II muscle fibers, or "fast twitch," with little to no decrease in type I muscle fibers, or "slow-twitch" muscle fibers. Deinervated type II fibers are often converted to type I fibers by reinnervation by slow type I fiber motor nerves.[12] Males are perhaps more susceptible for this aging-related switching of the myofiber type, as a recent research has shown a higher percentage of "slow twitch" muscle fibers in old compared to young males, but not in old compared to young females.[13]

Aging sarcopenic muscle shows an accumulation of mitochondrial DNA mutations, which has been demonstrated in various other cell types as well.[14] Clones with mitochondrial mutations build up in certain regions of the muscle, which goes along with an about fivefold increase in the absolute mtDNA copy number, that is, these regions are denser.[15] An apparent protective factor preventing cells' buildup of damaged mitochondria is sufficient levels of the protein BNIP3. Deficiency of BNIP3 leads to muscle inflammation and atrophy.[16]

Furthermore, not every muscle is as susceptible to the atrophic effects of aging. For example, in both humans[17] and mice[18] it has been shown that lower leg muscles are not as susceptible to aging as upper leg muscles. This could perhaps be explained by the differential distribution of myofiber type within each muscle group, but this is unknown.

Diagnosis

Multiple diagnostic criteria have been proposed by various expert groups and continues to be an area of research and debate. Despite the lack of a widely accepted definition, sarcopenia was assigned an ICD-10 code (M62.84) in 2016, recognizing it as a disease state.

Sarcopenia can be diagnosed when a patient has muscle mass that is at least two standard deviations below the relevant population mean and has a slow walking speed. The European Working Group on Sarcopenia in Older People (EWGSOP) developed a broad clinical definition for sarcopenia, designated as the presence of low muscle mass and either low muscular strength or low physical performance.[19] Other international groups have proposed criteria that include metrics on walking speed, distance walked in 6 minutes, or grip strength.[20] Hand grip strength alone has also been advocated as a clinical marker of sarcopenia that is simple and cost effective and has good predictive power, although it does not provide comprehensive information.[21]

There are screening tools for sarcopenia that assess patient reported difficulty in doing daily activities such as walking, climbing stairs or standing from a chair and have been shown to predict sarcopenia and poor functional outcomes.[22]

Biomarkers

As sarcopenia is a complex clinical diagnosis, circulating biomarkers have been proposed as proxies for early diagnosis and prediction as well as for follow-up and serial assessment of response to interventions.

Aging and sarcopenia are associated with an increase in inflammatory markers ("inflamm-aging") including: C-reactive protein, tumor necrosis factor, interleukin-8, interleukin-6, granulocyte-monocyte colony-stimulating factor, interferons, and serine protease A1.[23]

Changes in hormones associated with aging and sarcopenia include a reduction in the sex-hormones testosterone and dehydroepiandrosterone sulfate,[24] as well as reduced levels of circulating growth hormone and IGF-1.[25]

Circulating C-terminal agrin fragments (CAF) have been found to be higher in accelerated sarcopenic patients.[26]

Lower plasma levels of the amino acids leucine and isoleucine as well as other essential amino acids were found in frail older people compared to non-frail controls.[27] [28]

Alanine aminotransferase (ALT) is responsible for the transfer of the α-amino group from an α-amino acid to an α-keto acid, transforming pyruvate to alanine in skeletal muscle. Low circulating ALT is a marker for low muscle mass and sarcopenia,[29] as well for increased disease activity in patients with inflammatory bowel disease.[30]

Management

Exercise

Exercise remains the intervention of choice for sarcopenia, but translation of research findings into clinical practice is challenging. The type, duration and intensity of exercise are variable between studies, preventing a standardized exercise prescription for sarcopenia.[31] Lack of exercise is a significant risk factor for sarcopenia and exercise can dramatically slow the rate of muscle loss.[32] Exercise can be an effective intervention because aging skeletal muscle retains the ability to synthesize proteins in response to short-term resistance exercise.[33] Progressive resistance training in older adults can improve physical performance (gait speed) and muscular strength.[34] [35] [36] Increased exercise can produce greater numbers of cellular mitochondria, increase capillary density, and increase the mass and strength of connective tissue.[37]

Medication

There are currently no approved medications for the treatment of sarcopenia.[38] Testosterone or other anabolic steroids have also been investigated for treatment of sarcopenia, and seem to have some positive effects on muscle strength and mass, but cause several side effects and raise concerns of prostate cancer in men and virilization in women.[39] Additionally, recent studies suggest testosterone treatments may induce adverse cardiovascular events.[40] [41] [42]

DHEA and human growth hormone have been shown to have little to no effect in this setting. Growth hormone increases muscle protein synthesis and increases muscle mass, but does not lead to gains in strength and function in most studies.[43] This, and the similar lack of efficacy of its effector insulin-like growth factor 1 (IGF-1), may be due to local resistance to IGF-1 in aging muscle, resulting from inflammation and other age changes.

Other medications under investigation as possible treatments for sarcopenia include ghrelin, vitamin D, angiotensin converting enzyme inhibitors, and eicosapentaenoic acid.

Nutrition

Intake of calories and protein are important stimuli for muscle protein synthesis.[44] Older adults may not utilize protein as efficiently as younger people and may require higher amounts to prevent muscle atrophy. A number of expert groups have proposed an increase in dietary protein recommendations for older age groups to 1.0–1.2 g/kg body weight per day.[45] [46] Ensuring adequate nutrition in older adults is of interest in the prevention of sarcopenia and frailty, since it is a simple, low-cost treatment approach without major side effects.[47]

Supplements

A component of sarcopenia is the loss of ability for aging skeletal muscle to respond to anabolic stimuli such as amino acids, especially at lower concentrations. However, aging muscle retains the ability of an anabolic response to protein or amino acids at larger doses. Supplementation with larger doses of amino acids, particularly leucine has been reported to counteract muscle loss with aging.[48] Exercise may work synergistically with amino acid supplementation.

β-hydroxy β-methylbutyrate (HMB) is a metabolite of leucine that acts as a signalling molecule to stimulate protein synthesis.[49] It is reported to have multiple targets, including stimulating mTOR and decreasing proteasome expression. Its use to prevent the loss of lean body mass in older adults is consistently supported in clinical trials.[50] [51] [52] More research is needed to determine the precise effects of HMB on muscle strength and function in this age group.

Epidemiology

The prevalence of sarcopenia depends on the definition used in each epidemiological study. Estimated prevalence in people between the ages of 60-70 is 5-13% and increases to 11-50% in people more than 80 years of age. This equates to >50 million people and is projected to affect >200 million in the next 40 years given the rising population of older adults.[19]

Public health impact

Sarcopenia is emerging as a major public health concern given the increased longevity of industrialized populations and growing geriatric population. Sarcopenia is a predictor of many adverse outcomes including increased disability, falls and mortality.[53] [54] Immobility or bed rest in populations predisposed to sarcopenia can cause dramatic impact on functional outcomes. In the elderly, this often leads to decreased biological reserve and increased vulnerability to stressors known as the "frailty syndrome". Loss of lean body mass is also associated with increased risk of infection, decreased immunity, and poor wound healing. The weakness that accompanies muscle atrophy leads to higher risk of falls, fractures, physical disability, need for institutional care, reduced quality of life, increased mortality, and increased healthcare costs. This represents a significant personal and societal burden and its public health impact is increasingly recognized.

Research directions

There are significant opportunities to better understand the causes and consequences of sarcopenia and help guide clinical care. This includes elucidation of the molecular and cellular mechanisms of sarcopenia, further refinement of reference populations by ethnic groups, validation of diagnostic criteria and clinical tools, as well as tracking of incidence of hospitalization admissions, morbidity, and mortality. Identification and research on potential therapeutic approaches and timing of interventions is also needed.[55]

, there are no drugs approved to treat muscle wasting in people with chronic diseases, and there is therefore an unmet need for anabolic drugs with few side effects. One aspect hindering drug approval for treatments for cachexia and sarcopenia is disagreement in endpoints. Several clinical trials have found that selective androgen receptor modulators (SARMs) improve lean mass in humans, but it is not clear whether strength and physical function are also improved. After promising results in a phase II trial, a phase III trial of the SARM ostarine was proven to increase lean body mass but did not show significant improvement in function.[56] It and other drugs—such as the growth hormone secretagogue anamorelin—have been refused regulatory approval despite significant increases in lean mass due to a lack of evidence that they increased physical performance. Preventing decline in functionality was not considered an acceptable endpoint by the Food and Drug Administration. It is not known how SARMs interact with dietary protein intake and resistance training in people with muscle wasting.[57] [58]

Further reading

Notes and References

  1. Peterson SJ, Mozer M . Differentiating Sarcopenia and Cachexia Among Patients With Cancer . Nutrition in Clinical Practice . 32 . 1 . 30–39 . February 2017 . 28124947 . 10.1177/0884533616680354 . 206555460 .
  2. Ata AM, Kara M, Kaymak B, Özçakar L . Sarcopenia Is Not "Love": You Have to Look Where You Lost it! . American Journal of Physical Medicine & Rehabilitation . 99 . 10 . e119–e120 . October 2020 . 32084033 . 10.1097/PHM.0000000000001391 . 211245329 .
  3. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O . Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis . PLOS ONE . 12 . 1 . e0169548 . 2017 . 28095426 . 5240970 . 10.1371/journal.pone.0169548 . free . 2017PLoSO..1269548B .
  4. Ata AM, Kara M, Kaymak B, Gürçay E, Çakır B, Ünlü H, Akıncı A, Özçakar L . Regional and total muscle mass, muscle strength and physical performance: The potential use of ultrasound imaging for sarcopenia . Archives of Gerontology and Geriatrics . 83 . 55–60 . 2019 . 30953961 . 10.1016/j.archger.2019.03.014 . 96463073 .
  5. Ranasinghe C, Gamage P, Katulanda P, Andraweera N, Thilakarathne S, Tharanga P . Relationship between Body Mass Index (BMI) and body fat percentage, estimated by bioelectrical impedance, in a group of Sri Lankan adults: a cross sectional study . BMC Public Health . 13 . 797 . September 2013 . 24004464 . 3766672 . 10.1186/1471-2458-13-797 . free .
  6. Özkal Ö, Kara M, Topuz S, Kaymak B, Bakı A, Özçakar L . Assessment of core and lower limb muscles for static/dynamic balance in the older people: An ultrasonographic study . Age and Ageing . 48 . 6 . 881–887 . November 2019 . 31268513 . 10.1093/ageing/afz079 . free .
  7. Marcell TJ . Sarcopenia: causes, consequences, and preventions . The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences . 58 . 10 . M911–M916 . October 2003 . 14570858 . 10.1093/gerona/58.10.m911 . Review . free .
  8. Sayer AA, Syddall HE, Gilbody HJ, Dennison EM, Cooper C . Does sarcopenia originate in early life? Findings from the Hertfordshire cohort study . The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences . 59 . 9 . M930–M934 . September 2004 . 15472158 . 10.1093/gerona/59.9.M930 . free .
  9. Gale CR, Martyn CN, Kellingray S, Eastell R, Cooper C . Intrauterine programming of adult body composition . The Journal of Clinical Endocrinology and Metabolism . 86 . 1 . 267–272 . January 2001 . 11232011 . 10.1210/jcem.86.1.7155 . free .
  10. Ylihärsilä H, Kajantie E, Osmond C, Forsén T, Barker DJ, Eriksson JG . Birth size, adult body composition and muscle strength in later life . International Journal of Obesity . 31 . 9 . 1392–1399 . September 2007 . 17356523 . 10.1038/sj.ijo.0803612 . free .
  11. Ryall JG, Schertzer JD, Lynch GS . Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness . Biogerontology . 9 . 4 . 213–228 . August 2008 . 18299960 . 10.1007/s10522-008-9131-0 . Review . 8576449 .
  12. Doherty TJ . Invited review: Aging and sarcopenia . Journal of Applied Physiology . 95 . 4 . 1717–1727 . October 2003 . 12970377 . 10.1152/japplphysiol.00347.2003 . Review .
  13. de Jong JC, Attema BJ, van der Hoek MD, Verschuren L, Caspers MP, Kleemann R, van der Leij FR, van den Hoek AM, Nieuwenhuizen AG, Keijer J . Sex differences in skeletal muscle-aging trajectory: same processes, but with a different ranking . GeroScience . 45 . 4 . 2367–2386 . August 2023 . 36820956 . 10651666 . 10.1007/s11357-023-00750-4 . Original Research . free .
  14. Kauppila TE, Kauppila JH, Larsson NG . Mammalian Mitochondria and Aging: An Update . Cell Metabolism . 25 . 1 . 57–71 . January 2017 . 28094012 . 10.1016/j.cmet.2016.09.017 . 21609241 . free .
  15. Insalata F, Hoitzing H, Aryaman J, Jones NS . Stochastic survival of the densest and mitochondrial DNA clonal expansion in aging . Proceedings of the National Academy of Sciences of the United States of America . 119 . 49 . e2122073119 . December 2022 . 36442091 . 9894218 . 10.1073/pnas.2122073119 . free . 2022PNAS..11922073I .
  16. Irazoki A, Martinez-Vicente M, Aparicio P, Aris C, Alibakhshi E, Rubio-Valera M, Castellanos J, Lores L, Palacín M, Gumà A, Zorzano A, Sebastián D . Coordination of mitochondrial and lysosomal homeostasis mitigates inflammation and muscle atrophy during aging . Aging Cell . 21 . 4 . e13583 . April 2022 . 35263007 . 9009131 . 10.1111/acel.13583 .
  17. Naruse M, Trappe S, Trappe TA . Human skeletal muscle-specific atrophy with aging: a comprehensive review . Journal of Applied Physiology . 134 . 4 . 900–914 . April 2023 . 36825643 . 10069966 . 10.1152/japplphysiol.00768.2022 . Original Research . free .
  18. de Jong JC, Caspers MP, Worms N, Keijzer N, Kleemann R, Menke AL, Nieuwenhuizen AG, Keijer J, Verschuren L, van den Hoek AM . Translatability of mouse muscle-aging for humans: the role of sex . GeroScience . 46 . 3 . 3341–3360 . June 2024 . 38265577 . 11009184 . 10.1007/s11357-024-01082-7 . Original Research . free .
  19. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M . Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People . Age and Ageing . 39 . 4 . 412–423 . July 2010 . 20392703 . 2886201 . 10.1093/ageing/afq034 .
  20. Anker SD, Morley JE, von Haehling S . Welcome to the ICD-10 code for sarcopenia . Journal of Cachexia, Sarcopenia and Muscle . 7 . 5 . 512–514 . December 2016 . 27891296 . 5114626 . 10.1002/jcsm.12147 .
  21. Sayer AA . Sarcopenia . BMJ . 341 . aug10 2 . c4097 . August 2010 . 20699307 . 10.1136/bmj.c4097 . 220113690 .
  22. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE . SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes . Journal of Cachexia, Sarcopenia and Muscle . 7 . 1 . 28–36 . March 2016 . 27066316 . 4799853 . 10.1002/jcsm.12048 .
  23. Pan L, Xie W, Fu X, Lu W, Jin H, Lai J, Zhang A, Yu Y, Li Y, Xiao W . Inflammation and sarcopenia: A focus on circulating inflammatory cytokines . Experimental Gerontology . 154 . 111544 . October 2021 . 34478826 . 10.1016/j.exger.2021.111544 .
  24. Shin MJ, Jeon YK, Kim IJ . Testosterone and Sarcopenia . The World Journal of Men's Health . 36 . 3 . 192–198 . September 2018 . 29756416 . 6119844 . 10.5534/wjmh.180001 .
  25. Bartke A . Growth Hormone and Aging: Updated Review . The World Journal of Men's Health . 37 . 1 . 19–30 . January 2019 . 29756419 . 6305861 . 10.5534/wjmh.180018 .
  26. Qaisar R, Karim A, Muhammad T, Shah I, Khan J . Prediction of sarcopenia using a battery of circulating biomarkers . Scientific Reports . 11 . 1 . 8632 . April 2021 . 33883602 . 8060253 . 10.1038/s41598-021-87974-6 .
  27. Adav SS, Wang Y . Metabolomics Signatures of Aging: Recent Advances . Aging and Disease . 12 . 2 . 646–661 . April 2021 . 33815888 . 7990359 . 10.14336/AD.2020.0909 .
  28. Calvani R, Picca A, Marini F, Biancolillo A, Gervasoni J, Persichilli S, Primiano A, Coelho-Junior HJ, Bossola M, Urbani A, Landi F, Bernabei R, Marzetti E . A Distinct Pattern of Circulating Amino Acids Characterizes Older Persons with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study . Nutrients . 10 . 11 . 1691 . November 2018 . 30404172 . 6265849 . 10.3390/nu10111691 . free .
  29. Portal D, Hofstetter L, Eshed I, Dan-Lantsman C, Sella T, Urban D, Onn A, Bar J, Segal G . L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients . English . Cancer Management and Research . 11 . 2579–2588 . 2019-04-01 . 31114324 . 6497853 . 10.2147/CMAR.S195869 . free .
  30. Shafrir A, Katz LH, Shauly-Aharonov M, Zinger A, Safadi R, Stokar J, Kalisky I . Low ALT Is Associated with IBD and Disease Activity: Results from a Nationwide Study . Journal of Clinical Medicine . 13 . 7 . 1869 . March 2024 . 38610634 . 11012492 . 10.3390/jcm13071869 . free .
  31. Sayer AA . Sarcopenia the new geriatric giant: time to translate research findings into clinical practice . Age and Ageing . 43 . 6 . 736–737 . November 2014 . 25227204 . 10.1093/ageing/afu118 . free .
  32. Abate M, Di Iorio A, Di Renzo D, Paganelli R, Saggini R, Abate G . Frailty in the elderly: the physical dimension . Europa Medicophysica . 43 . 3 . 407–415 . September 2007 . 17117147 .
  33. Yarasheski KE . Exercise, aging, and muscle protein metabolism . The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences . 58 . 10 . M918–M922 . October 2003 . 14570859 . 10.1093/gerona/58.10.m918 . Review . free .
  34. Liu CJ, Latham NK . Progressive resistance strength training for improving physical function in older adults . The Cochrane Database of Systematic Reviews . 2009 . 3 . CD002759 . July 2009 . 19588334 . 4324332 . 10.1002/14651858.cd002759.pub2 .
  35. Valenzuela PL, Castillo-García A, Morales JS, Izquierdo M, Serra-Rexach JA, Santos-Lozano A, Lucia A . Physical Exercise in the Oldest Old . Comprehensive Physiology . 9 . 4 . 1281–1304 . September 2019 . 31688965 . 10.1002/cphy.c190002 . Wiley . 978-0-470-65071-4 . Terjung R . 1st .
  36. Fragala MS, Cadore EL, Dorgo S, Izquierdo M, Kraemer WJ, Peterson MD, Ryan ED . Resistance Training for Older Adults: Position Statement From the National Strength and Conditioning Association . Journal of Strength and Conditioning Research . 33 . 8 . 2019–2052 . August 2019 . 31343601 . 10.1519/JSC.0000000000003230 .
  37. Book: Betts JG, Desaix P, Johnson E, Johnson JE, Korol O, Kruse D, Poe B, Wise J, Womble MD, Young KA . Anatomy & Physiology. Houston. OpenStax CNX. 978-1-947172-04-3. June 8, 2023. 10.6 Exercise and muscle performance.
  38. Phillips SM . Nutritional supplements in support of resistance exercise to counter age-related sarcopenia . Advances in Nutrition . 6 . 4 . 452–460 . July 2015 . 26178029 . 4496741 . 10.3945/an.115.008367 .
  39. Wakabayashi H, Sakuma K . Comprehensive approach to sarcopenia treatment . Current Clinical Pharmacology . 9 . 2 . 171–180 . May 2014 . 24219006 . 10.2174/1574884708666131111192845 .
  40. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Hoover RN . Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men . PLOS ONE . 9 . 1 . e85805 . 29 January 2014 . 24489673 . 3905977 . 10.1371/journal.pone.0085805 . 2014PLoSO...985805F . free .
  41. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM . Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels . JAMA . 310 . 17 . 1829–1836 . November 2013 . 24193080 . 10.1001/jama.2013.280386 .
  42. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S . Adverse events associated with testosterone administration . The New England Journal of Medicine . 363 . 2 . 109–122 . July 2010 . 20592293 . 3440621 . 10.1056/NEJMoa1000485 .
  43. Sakuma K, Yamaguchi A . Sarcopenia and age-related endocrine function . International Journal of Endocrinology . 2012 . 127362 . 28 May 2012 . 22690213 . 3368374 . 10.1155/2012/127362 . free .
  44. Robinson SM, Reginster JY, Rizzoli R, Shaw SC, Kanis JA, Bautmans I, Bischoff-Ferrari H, Bruyère O, Cesari M, Dawson-Hughes B, Fielding RA, Kaufman JM, Landi F, Malafarina V, Rolland Y, van Loon LJ, Vellas B, Visser M, Cooper C . Does nutrition play a role in the prevention and management of sarcopenia? . Clinical Nutrition . 37 . 4 . 1121–1132 . August 2018 . 28927897 . 5796643 . 10.1016/j.clnu.2017.08.016 .
  45. Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, Phillips S, Sieber C, Stehle P, Teta D, Visvanathan R, Volpi E, Boirie Y . Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group . Journal of the American Medical Directors Association . 14 . 8 . 542–559 . August 2013 . 23867520 . 10.1016/j.jamda.2013.05.021 . free .
  46. Deutz NE, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, Cederholm T, Cruz-Jentoft A, Krznariç Z, Nair KS, Singer P, Teta D, Tipton K, Calder PC . Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group . Clinical Nutrition . 33 . 6 . 929–936 . December 2014 . 24814383 . 4208946 . 10.1016/j.clnu.2014.04.007 .
  47. Tessier AJ, Chevalier S . An Update on Protein, Leucine, Omega-3 Fatty Acids, and Vitamin D in the Prevention and Treatment of Sarcopenia and Functional Decline . Nutrients . 10 . 8 . 1099 . August 2018 . 30115829 . 6116139 . 10.3390/nu10081099 . free .
  48. Fujita S, Volpi E . Amino acids and muscle loss with aging . The Journal of Nutrition . 136 . 1 Suppl . 277S–280S . January 2006 . 16365098 . 3183816 . 10.1093/jn/136.1.277S .
  49. Argilés JM, Campos N, Lopez-Pedrosa JM, Rueda R, Rodriguez-Mañas L . Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease . Journal of the American Medical Directors Association . 17 . 9 . 789–796 . September 2016 . 27324808 . 10.1016/j.jamda.2016.04.019 . free .
  50. Brioche T, Pagano AF, Py G, Chopard A . Muscle wasting and aging: Experimental models, fatty infiltrations, and prevention . Molecular Aspects of Medicine . 50 . 56–87 . August 2016 . 27106402 . 10.1016/j.mam.2016.04.006 . 29717535 .
  51. Wu H, Xia Y, Jiang J, Du H, Guo X, Liu X, Li C, Huang G, Niu K . Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults: a systematic review and meta-analysis . Archives of Gerontology and Geriatrics . 61 . 2 . 168–175 . September 2015 . 26169182 . 10.1016/j.archger.2015.06.020 .
  52. Holeček M . Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions . Journal of Cachexia, Sarcopenia and Muscle . 8 . 4 . 529–541 . August 2017 . 28493406 . 5566641 . 10.1002/jcsm.12208 .
  53. Xia L, Zhao R, Wan Q, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu X . Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies . Cancer Medicine . 9 . 21 . 7964–7978 . November 2020 . 32924316 . 7643685 . 10.1002/cam4.3428 .
  54. Rodrigues F, Domingos C, Monteiro D, Morouço P . A Review on Aging, Sarcopenia, Falls, and Resistance Training in Community-Dwelling Older Adults . International Journal of Environmental Research and Public Health . 19 . 2 . 874 . January 2022 . 35055695 . 8775372 . 10.3390/ijerph19020874 . free .
  55. Sayer AA, Robinson SM, Patel HP, Shavlakadze T, Cooper C, Grounds MD . New horizons in the pathogenesis, diagnosis and management of sarcopenia . Age and Ageing . 42 . 2 . 145–150 . March 2013 . 23315797 . 3575121 . 10.1093/ageing/afs191 .
  56. Rolland Y, Dray C, Vellas B, Barreto PS . Current and investigational medications for the treatment of sarcopenia . Metabolism . 149 . 155597 . December 2023 . 37348598 . 10.1016/j.metabol.2023.155597 . 259232987 .
  57. Fonseca GW, Dworatzek E, Ebner N, Von Haehling S . Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials . Expert Opinion on Investigational Drugs . 29 . 8 . 881–891 . August 2020 . 32476495 . 10.1080/13543784.2020.1777275 . 219174372 .
  58. Christiansen AR, Lipshultz LI, Hotaling JM, Pastuszak AW . Selective androgen receptor modulators: the future of androgen therapy? . Translational Andrology and Urology . 9 . Suppl 2 . S135–S148 . March 2020 . 32257854 . 7108998 . 10.21037/tau.2019.11.02 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sarcopenia".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.